WallStSmart

Agilent Technologies Inc (A)vsMainz Biomed BV (MYNZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 1070452% more annual revenue ($7.07B vs $659,940). A leads profitability with a 18.3% profit margin vs 0.0%. A earns a higher WallStSmart Score of 61/100 (C+).

A

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 7.3Quality: 5.3
Piotroski: 3/9Altman Z: 1.99

MYNZ

Avoid

18

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 6/9Altman Z: -14.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-318.5%)

Margin of Safety

-318.5%

Fair Value

$30.80

Current Price

$112.98

$82.18 premium

UndervaluedFair: $30.80Overvalued

Intrinsic value data unavailable for MYNZ.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 8.5/10
Return on EquityProfitability
20.0%9/10

Every $100 of equity generates 20 in profit

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

MYNZ1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Areas to Watch

A3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-3.6%2/10

Earnings declined 3.6%

MYNZ4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.90M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Debt/EquityHealth
1.233/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : MYNZ

The strongest argument for MYNZ centers on Price/Book.

Bear Case : A

The primary concerns for A are Altman Z-Score, Piotroski F-Score, EPS Growth.

Bear Case : MYNZ

The primary concerns for MYNZ are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

A profiles as a mature stock while MYNZ is a value play — different risk/reward profiles.

A carries more volatility with a beta of 1.31 — expect wider price swings.

A is growing revenue faster at 7.0% — sustainability is the question.

A generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

A scores higher overall (61/100 vs 18/100), backed by strong 18.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Mainz Biomed BV

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.

Want to dig deeper into these stocks?